Market Overview

UPDATE: Deutsche Bank Raises PT on Tenet Healthcare Corp. on Continued Good Outlook

Share:
Related THC
Credit Suisse: A Beaten Down Tenet Healthcare 'Still Strong'
UPDATE: Tenet Healthcare Reports Q4 Profit
Tenet Healthcare's (THC) CEO Trevor Fetter on Q4 2014 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Friday, Deutsche Bank reiterated its Buy rating on Tenet Healthcare Corp. (NYSE: THC), and raised its price target from $43.00 to $46.00.

Deutsche Bank noted, “We continue to believe an upside risk to THC's valuation is its Conifer segment, which is growing at a faster pace than the overall enterprise and could begin to differentiate THC's multiple once Conifer's stand-alone (non-THC) EBITDA is convincing enough to the market. Finally, we note that our valuation framework does not include THC's NOL, which provides an additional $3-4 of cushion to the valuation. Key risks include: Medicare/Medicaid cuts, implementation risks of PPACA, HCIT conversions, M&A integration, state exposures in Texas, Florida and California.”

Tenet Healthcare Corp. closed on Thursday at $41.76.

Latest Ratings for THC

DateFirmActionFromTo
Feb 2015CitigroupMaintainsBuy
Feb 2015BMO CapitalUpgradesMarket PerformOutperform
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (THC)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→